Confluence Investment Management LLC Reduces Stock Holdings in Charles River Laboratories International, Inc. $CRL

Posted by Brian Himes on Aug 4th, 2026

Confluence Investment Management LLC lessened its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 8.9% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 91,632 shares of the medical research company’s stock after selling 8,902 shares during the period. Confluence Investment Management LLC’s holdings in Charles River Laboratories International were worth $20,781,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Invesco Ltd. grew its stake in Charles River Laboratories International by 115.8% in the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after acquiring an additional 1,446,972 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new position in Charles River Laboratories International during the fourth quarter worth about $176,478,000. Victory Capital Management Inc. raised its position in Charles River Laboratories International by 9,938.8% during the fourth quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after acquiring an additional 684,586 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Charles River Laboratories International by 1,491.1% in the third quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after purchasing an additional 575,039 shares in the last quarter. Finally, Amundi lifted its holdings in shares of Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after purchasing an additional 492,301 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the transaction, the director owned 31,596 shares of the company’s stock, valued at $7,109,100. This represents a 70.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on CRL shares. Morgan Stanley raised their price objective on shares of Charles River Laboratories International from $220.00 to $260.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Mizuho upped their target price on Charles River Laboratories International from $192.00 to $230.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Evercore reiterated an “outperform” rating and set a $220.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Finally, CLSA downgraded Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target for the company. in a research report on Monday, July 20th. Eleven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $220.75.

Check Out Our Latest Stock Report on CRL

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $230.58 on Tuesday. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. The firm has a market cap of $11.11 billion, a PE ratio of -61.33, a P/E/G ratio of 2.59 and a beta of 1.38. The firm has a 50 day simple moving average of $207.99 and a 200-day simple moving average of $188.00. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $242.73.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The firm had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. Charles River Laboratories International’s revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.

About Charles River Laboratories International

(Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.